Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

Acarix CADScor® System Gains HealthChoice Reimbursement Coverage

Acarix

Malmö, Sweden – Acarix, a global leader in AI- and acoustics-based cardiac diagnostics, is pleased to announce that HealthChoice, a self-funded insurance plan administered by the State of Oklahoma, has implemented reimbursement coverage for the CADScor® System effective October 1, 2025. The coverage applies across both physician office and hospital settings.

HealthChoice provides benefits to more than 150,000 members, including state and local government employees, educators, retirees, and their dependents. The CADScor® System offers a rapid, non-invasive acoustic diagnostic tool that enables physicians to risk stratify significant coronary artery disease in just minutes, supporting improved patient outcomes while reducing unnecessary downstream testing and costs.
“This milestone represents an important step forward in expanding access to the CADScor® System,” said Aamir Mahmood, CEO of Acarix. “With HealthChoice coverage in place, thousands of patients in Oklahoma will now benefit from earlier, more efficient, and cost-effective cardiac diagnostics.”

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 40,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX) and cross-traded on the OTCQB market in the US (ticker: ACIXF). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com

For more information, contact
Macie May, phone +1 405 517 5161, email mmay@saxum.com

Attachments
Acarix CADScor® System Gains HealthChoice Reimbursement Coverage

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.